Hirotaka Matsumoto

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya et al. · European Journal of Cancer · 2021 · 89 citations

Medicine, Oncology, Pharmacology +12

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

Go Saito, Yuko Oya, Yoshihiko Taniguchi et al. · Lung Cancer · 2021 · 58 citations

Medicine, Oncology, Radiation Oncology +15

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya et al. · Investigational New Drugs · 2019 · 54 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya et al. · Investigational New Drugs · 2019 · 53 citations

Pharmacy, Oncology, Pharmacotherapy +16

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer

Yoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara et al. · JAMA Oncology · 2023 · 50 citations · Full text

Medicine, Oncology, Pharmacology +17